X4 secures up to $150M debt facility with K2 HealthVentures
X4 Pharmaceuticals secured a $150M senior secured term loan facility with K2 HealthVentures to repay existing debt and fund corporate activities. This deal strengthens financial flexibility ahead of anticipated FDA approval for mavorixafor.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed